By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


Company News
Cellceutix (CTIX) Completes Patient Enrollment Of Final Cohort In Phase II Trial Of Brilacidin For Inflammatory Bowel Disease; Topline Results Anticipated In July 5/18/2017 10:15:03 AM
Cellceutix (CTIX) Provides Corporate Update; Significant Milestones Ahead As Multiple Mid-Phase Clinical Trials Set To Conclude 5/10/2017 8:40:00 AM
Cellceutix (CTIX) Announces Details For Upcoming Investor And Shareholder Presentations 4/20/2017 10:25:34 AM
Cellceutix (CTIX) CEO Discusses Brilacidin Following Interim Trial Results For Treating Oral Mucositis And Inflammatory Bowel Disease 4/10/2017 11:06:10 AM
Cellceutix (CTIX) Takes on Anonymous Blogger, Calls Mako Research's Actions "Criminal" 3/20/2017 6:13:40 AM
Cellceutix (CTIX) Provides Update On Developing P53 Drug Candidate Kevetrin As An Oral Anti-Cancer Agent 3/6/2017 8:38:42 AM
Cellceutix (CTIX) CEO Unhinged After Anonymous Short Trader's Attacks 1/23/2017 6:10:24 AM
Anonymous Short Trader Attacks Cellceutix (CTIX) Again 1/19/2017 5:59:44 AM
A Year After a Scathing Attack By a Short Seller, Cellceutix (CTIX) Eyes the Nasdaq and Big Investors 8/17/2016 5:47:56 AM
Cellceutix (CTIX) Files Motion To Dismiss Complaint Filed By The Rosen Law Firm 2/12/2016 9:24:52 AM